13 Patents
- 0 cites
- US124922572025Anti-ctla-4 Antibodies and Methods of Use Thereof
MEMORIAL SLOAN-KETTERING CANCER CENTER
0 cites - US123970292025Use of MVA or MVADELTAE3L as Immunotherapeutic Agents Against Solid Tumors
MEMORIAL SLOAN KETTERING CANCER CENTER
0 cites - US123313592025Neoantigens and Uses Thereof for Treating Cancer
Memorial Sloan Kettering Cancer Center
0 cites - 0 cites
- US122460662025Anti-ctla-4 Antibodies and Methods of Use Thereof
Memorial Sloan Kettering Cancer Center
0 cites - US120362792024Recombinant MVA or MVADELE3L Expressing Human FLT3L and Use Thereof as Immuno-therapeutic Agents Against Solid Tumors
Memorial Sloan Kettering Cancer Center
0 cites - 0 cites
- US119865032024Replication Competent Attenuated Vaccinia Viruses with Deletion of Thymidine Kinase with and Without the Expression of Human Flt3l or GM-CSF for Cancer Immunotherapy
Memorial Sloan Kettering Cancer Center
0 cites - US118979622024Anti-gitr Antibodies and Methods of Use Thereof
Ludwig Institute For Cancer Research Ltd.
0 cites - US118849392024Vaccinia Virus Mutants Useful for Cancer Immunotherapy
Memorial Sloan Kettering Cancer Center
0 cites - US116387552023Anti-ctla-4 Antibodies and Methods of Use Thereof
Memorial Sloan-kettering Cancer Center
0 cites - US115410872023Replication Competent Attenuated Vaccinia Viruses with Deletion of Thymidine Kinase with and Without the Expression of Human Flt3l or GM-CSF for Cancer Immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER
0 cites